Dosing underway in Apellis Pharma's late-stage program of APL-2 in geographic atrophy

Sep. 12, 2018 8:00 AM ETApellis Pharmaceuticals, Inc. (APLS)By: Douglas W. House, SA News Editor
  • The first participant has been dosed in a Phase 3 clinical trial, OAKS, evaluating Apellis Pharmaceuticals' (NASDAQ:APLS) APL-2 in patients with geographic atrophy (GA) (advanced age-related macular degeneration), a condition affecting ~1M Americans.
  • An identical Phase 3, DERBY, has just begun enrollment.
  • The primary endpoint for both is the change from baseline to month 12 in total area of GA lesions in the study eye. The estimated primary completion date for both is March/April 2021.
  • APL-2 is a complement 3 (C3) inhibitor.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.